Skip to content
Wyss AI partnership

Dandelion Science and the Wyss Center announce AI partnership

Share this article

The Wyss Center for Bio and Neuroengineering and Dandelion Science announced a partnership focused on a cutting-edge generative AI neuromodulation platform that could speed the development of safe, non-invasive ways of treating neurodegenerative and neuropsychiatric disorders.



The platform harnesses the power of generative artificial intelligence (AI) to synthesise, on demand, precision sensory stimulation therapies.

Dr. Erwin Böttinger, Director of the Wyss Center, expressed his enthusiasm for the collaboration, stating, “We are delighted to invest in and partner with Dandelion Science. The promise of generative AI as a new therapeutic paradigm for brain disorders is exciting. AI guided neuromodulation is a key focus area for the Wyss Center, to develop smarter therapies for neurologic and mental health disorders by combining artificial intelligence and novel non-invasive neuromodulation techniques targeting deep brain structures. Dandelion’s innovative deep tech approach, robust intellectual property portfolio, and exceptional team make them an ideal partner. We look forward to the transformative impact this technology could have on patients worldwide.”

The collaboration with the Swiss-based Wyss Center leverages significant resources and capital over four years, providing Dandelion Science with rapid access to diverse clinical partners, extensive expertise in neuroscience and neurotechnology development, and integration into a broader AI and neurotechnology ecosystem.

Adam Hanina, CEO of Dandelion Science and newly appointed Expert-in-Residence at the Wyss Center Geneva, said, “Generative neuromodulation is poised to become a multi-billion-dollar market in the coming years. Dandelion’s novel computational approach, which emulates the way in which the brain itself processes information, holds promise for developing therapies that precisely match the complex dysfunctions they are intended to treat. We deliberately sought out the Wyss Center as a research foundation so we could work together as ethical pioneers on this potentially revolutionary technology. The new partnership not only validates Dandelion’s efforts but also significantly enhances our capability to innovate and deliver value.”




Source: press release